JAK2 MUTATION, TNF-Α AND IL 6 PREDICT RESPONSE TO JAK INHIBITOR IN RHEUMATOID ARTHRITIS PATIENTS

被引：0
|
作者：
Hussein, Y. Adel Abdelsalam [1 ]
Sadeq, Y. [2 ]
机构：
[1] Mansoura Univ Hosp, Rheumatol, Mansoura, Egypt
[2] Mansoura Univ Hosp, Clin Pathol, Mansoura, Egypt
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; Prognostic factors;
D O I：
10.1136/annrheumdis-2023-eular.840
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0358
引用
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [31] Don't judge a JAK2 inhibitor by spleen response alone
    Mascarenhas, John
    Hoffman, Ronald
    LANCET HAEMATOLOGY, 2018, 5 (02): : E56 - E57
  • [32] A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients
    Elahee, Mehreen
    Marks, Kathryne
    Adejoorin, Ifeoluwakiisi
    Chen, Lin
    Todd, Derrick
    Coblyn, Jonathan
    Massarotti, Elena
    Ritter, Susan
    Weinblatt, Michael
    Solomon, Daniel
    Rao, Deepak
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 19 - 21
  • [33] A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study
    Chin-Yee, Benjamin
    Bhai, Pratibha
    Cheong, Ian
    Matyashin, Maxim
    Hsia, Cyrus C.
    Kawata, Eri
    Ho, Jenny M.
    Levy, Michael A.
    Stuart, Alan
    Lin, Hanxin
    Chin-Yee, Ian
    Kadour, Mike
    Sadikovic, Bekim
    Lazo-Langner, Alejandro
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (08) : 1828 - 1833
  • [34] HYPOGLYCAEMIA FOLLOWING JAK INHIBITOR TREATMENT IN DIABETES MELLITUS PATIENTS WITH RHEUMATOID ARTHRITIS
    van Lint, J.
    Van Hunsel, F.
    Tas, S.
    Nurmohamed, M.
    Vonkeman, H.
    Hebing, R.
    Hoentjen, F.
    van Doorn, M.
    van den Bemt, B.
    van Puijenbroek, E.
    Jessurun, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 578 - 579
  • [35] Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
    Kivitz, A. J.
    Gutierrez-Urena, S. R.
    Poiley, J.
    Genovese, M. C.
    Kristy, R.
    Shay, K.
    Wang, X.
    Garg, J. P.
    Zubrzycka-Sienkiewicz, A.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (04) : 709 - 719
  • [36] A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study
    Benjamin Chin-Yee
    Pratibha Bhai
    Ian Cheong
    Maxim Matyashin
    Cyrus C. Hsia
    Eri Kawata
    Jenny M. Ho
    Michael A. Levy
    Alan Stuart
    Hanxin Lin
    Ian Chin-Yee
    Mike Kadour
    Bekim Sadikovic
    Alejandro Lazo-Langner
    Journal of General Internal Medicine, 2023, 38 : 1828 - 1833
  • [37] Evaluation of Jak2 exon 12 mutation in patients with polycythemia vera
    Asad, Fatemeh Zadeh
    Saki, Najmaldin
    Asl, Javad Mohammadi
    Vosoughi, Tina
    Asadi, Zari Tahannejad
    CLINICAL CANCER INVESTIGATION JOURNAL, 2020, 9 (06): : 244 - 248
  • [38] JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F
    Kopp, Nadja
    Van der Zwet, Jordy C.
    Layer, Jacob
    Weigert, Oliver
    Vangrevelinghe, Eric
    Yoda, Akinori
    Radimerski, Thomas
    Weinstock, David
    BLOOD, 2013, 122 (21)
  • [39] Mutation profile of JAK2, EPOR and CALR genes in polycythemia patients
    Anbinselvama, Arularasan
    Sidharthan, Neeraj
    Vidyadharan, Geeta
    Kurian, Jessy
    Biswas, Lalitha
    BLOOD CELLS MOLECULES AND DISEASES, 2020, 82
  • [40] The JAK2 V617F mutation in patients with anaemia
    S. E. Langabeer
    Irish Journal of Medical Science (1971 -), 2017, 186 : 349 - 350
12345